Table 3.
Examples of ocular and transdermal delivery systems based on EC.
| Drug Dosage Form | Active Substance | Used Excipients | EC Role | Reference |
|---|---|---|---|---|
| Ocular formulations | ||||
| ocular inserts | brimonidine | sodium alginate, EC | hydrophobic, sustained release coating | [71] |
| ocular inserts | ciprofloxacin | gelatin, EC | rate-controlling, increasing residence time membrane | [72] |
| ocular insert | acyclovir | sodium alginate, EC | rate-controlling membrane | [73] |
| in situ ophthalmic hydrogel | besifloxacin | sodium alginate, xanthan gum, EC | increase the pre-corneal residence time | [74] |
| minitablet | ciprofloxacin | HPMC, sodium carboxymethyl cellulose, EC, hydroxyethyl cellulose, carbopol | sustained release | [75] |
| Transdermal formulations | ||||
| transdermal patch | amlodipine | EC | sustained release | [76] |
| transdermal patch | flurbiprofen | EC, propylene glycol, dibutyl phthalate | constant drug release | [77] |
| transdermal delivery system | topiramate | EC, povidone, Eudragit L 100, carbopol | extended release | [78] |
| transdermal patch | dexibuprofen | EC, povidone, di-N-butyl phthalate | matrix formation | [79] |
| transdermal patch | centchroman | EC, polydimethylsiloxane, propylene glycol, Di-n-butyl-phthalate | Film-forming polymer | [80] |